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Introduction
Colorectal cancer is a common cancer and a major
cause of morbidity and mortality worldwide. Middle
to lower rectal cancer, a challenge for surgeons, is prob-
lematic. Surgical therapy for rectal cancer has evolved
since Ernest Miles first described the abdominoper-
ineal resection in 1908.1 By the 1920s, he had reduced
the recurrence rate from almost 100% to approximately
30%,2 thus ensuring that this technique was the gold
standard at that time while advocating extensive aggres-
sive cancer therapy. In retrospect, it is perplexing that
such extreme surgery was standard, given its consider-
able local failure rate and its potential to result in uri-
nary, sexual, and gastrointestinal dysfunction. Several
modifications were proposed to promote locoregional
control and survival, with little success.3,4 Better
suture material, as well as devices enabling lower
anastomosis, led to a shift toward sphincter-saving
approaches with respect to cancer of the rectum. Ante-
rior resection replaced abdominoperineal resection as
the mainstay of therapy, although adequate consider-
ation of circumferential margins and lymph node har-
vests were often neglected in early reports in the 1950s.
Not surprisingly, there was concern that sphincter-
saving surgery might increase local recurrence. It was
in this setting that total mesorectal excision (TME)
was first described in 1982 by Heald and colleagues;5
TME reduced recurrence rates to less than 10%.6
Neoadjuvant concurrent chemoradiotherapy (CCRT),
introduced in the last decade, has led to local control
for advanced rectal cancer to a higher percentage of
R0 resection (margin clear under microscopic exami-
nation) and a lower recurrence rate.7
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Methods
From January 2005 to June 2007, 46 patients with
locally advanced (fixed tumor by digital rectal exam
or T3–4 tumor by computed tomography [CT]/
sonography) rectal cancer who received CCRT were
retrospectively reviewed. The neoadjuvant CCRT for
locally advanced rectal cancer in our hospital was 
5-fluorouracil 400 mg/m2 plus leucovorin 20 mg/m2
intravenously for 1 hour, on days 1–4 and 29–32, con-
current with radiotherapy (200 cGy/day, Monday–
Friday, for 5 weeks).
Three of the patients, who achieved confirmed clin-
ical complete response by CT scan and physical exam-
ination, and who received only local excision, were
excluded, leaving 43 patients included in our study.
Based on post-CCRT CT and digital rectal examination,
we defined the clinical response. Five (12%) patients had
complete response and 29 (67%) had partial response;
the overall response rate was 79%. Several parameters,
including local recurrence, curative resection (R0 resec-
tion), and postoperative complications, were evalu-
ated. The method of statistical analysis for disease-free
survival time and overall survival time was Kaplan-
Meier survival analysis, whereas that for postoperative
complications, metastasis, curative resection rate and
Duke’s stage was Fisher’s exact test.
Results
Patients’ characteristics are shown in Table 1. Most of
them received TME, and almost all had protective
ileostomy. Curative resection rate (R0 resection rate)
was higher in the responding group (97%) than in the
non-responding group (66.7%), with statistical signif-
icance (p=0.024). As shown in Table 2, the local recur-
rence rate was low in the responding group (5.9%)
compared with the non-responding group (p = 0.002).
Disease-free survival was also higher in the responding
group, with marginal statistical significance (p = 0.06).
Otherwise, there was no significant difference between
groups in overall survival time. The anastomotic leak-
age rate was high, up to 25% in both groups. Mean hos-
pital stay was 11.5 days, with no significant difference
between groups. As can be seen in Table 3, the risk fac-
tors for local recurrence were high Duke grade and in-
complete resection (R1 [microscopic margin positive]
and R2 [gross margin positive] resection). Incomplete
resection rate was higher in the non-responding
group. During the period of CCRT, there was only 
1 patient who developed grade III neutropenia, and
no distant metastatic lesions occurred.
Discussion
Incomplete resection of rectal cancer eventually results
in local recurrence and death. To improve this, Miles1
introduced abdominoperineal resection in the early
1900s. With evolving instruments, a sphincter-saving
procedure was performed in rectal cancer. Heald et al5
developed TME in 1982, which decreased the local
recurrence rate to less than 10%. In locally advanced
rectal cancer, it remained a challenge until the early
1990s. Neoadjuvant CCRT8,9 offered the possibility of
tumor-shrinking, hence making curative resection pos-
sible. In our series, 43 patients received neoadjuvant
CCRT, with a mean follow-up time of 1.5 years. The
overall recurrence rate was 16.3%, including 5.9% in
the responding group and 55.6% in the non-responding
group, respectively (p = 0.002). The curative resection
rates were 97.1% in the responding group and 66.7%
in the non-responding group, respectively (p = 0.024).
It is well known that by inducing tumor shrinkage and
hence leading to further curative resection, CCRT
improved the local control rate. It could have caused
other problems if we had saved the sphincter in the
non-responding group. The anastomotic leakage rate
was 27.8%, similar in both groups. As most of our
patients had received protective ileostomy, the prob-
lem was solved and the mean hospital stay was only
11.5 days.
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Table 1. Patient characteristics*
Age (yr) 55.57 ± 13.10



















*Data presented as mean ± standard deviation or n (%). TME = total
mesorectal excision.
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Table 2. Response*
RR Complete + partial response No response p
Anal verge (cm) 5 (3–13) 5 (4–8) 0.861†
DFT (mo) 16 (4–36) 13 (4–34) 0.060‡
OST (mo) 17.5 (5–36) 25 (14–34) 0.206‡
Stay (d) 9.5 (6–28) 14 (8–26) 0.705†
U/M/L 1.000§
L 26 (76.5) 8 (88.9)
M 6 (17.6) 1 (11.1)
U 2 (5.9) 0 (0.0)
Complications 0.225§
+ 2 (8.7) 2 (28.6)
− 21 (91.3) 5 (71.4)
Leak 1.000§
+ 8 (28.6) 2 (25.0)
− 20 (71.4) 6 (75.0)
Pelvic abscess 0.188§
+ 2 (5.9) 2 (22.2)
− 32 (94.1) 7 (77.8)
Local recurrence 0.002§
+ 2 (5.9) 5 (55.6)
− 32 (94.1) 4 (44.4)
Metastasis 0.026§
+ 3 (8.8) 4 (44.4)
− 31 (91.2) 5 (55.6)
Stage (Duke) 0.001||
0 5 (14.7) 0 (0.0)
A + B 21 (61.8) 1 (11.1)
B2 0 (0.0) 2 (22.2)
C 8 (23.5) 6 (66.7)
CRM 0.024§
R0 33 (97.1) 6 (66.7)
R1 + R2 1 (2.9) 3 (33.3)
Poorly/A-V-N 0.238§
+ 10 (29.4) 5 (55.6)
− 24 (70.6) 4 (44.4)
Node 0.040§
+ 8 (23.5) 6 (66.7)
− 26 (76.5) 3 (33.3)
Schedule 1.000§
Others 9 (26.5) 2 (22.2)
TME + loop 25 (73.5) 7 (77.8)
Laparoscopy/open 0.455§
Laparoscopy 21 (61.8) 4 (44.4)
Open 13 (38.2) 5 (55.6)
*Data presented as median (range) or n (%); †Mann-Whitney U test; ‡Kaplan-Meier survival analysis; §Fisher’s exact test; ||Pearson’s χ2 test. DFT = disease-
free survival time; OST = overall survival time; U = upper rectum; M = middle rectum; L = lower rectum; CRM = circumferential radial margin; A-V-N = cancer
invasion to artery, vein or nerve; TME = total mesorectal excision.
In our study, major complications were accept-
able: < 10%, similar to other series.10 Thirty-two pa-
tients received sphincter-saving surgery, and 5 of them
(15.6%) converted to permanent stoma. In our series,
the toxicity related to CCRT was mild, as in other
reports. There were 20–30% of patients who developed
grade I–II nausea/vomiting and grade I–II neutrope-
nia, and only 1 patient developed grade III neutrope-
nia. No metastatic lesions occurred during the period
of CCRT.
In conclusion, neoadjuvant CCRT gives a high
chance of tumor shrinkage, and hence improves the
curative resection and local control rates. Patients
who responded to CCRT had a better local control
rate with tolerable adverse effects.
References
1. Miles WE. A method for performing abdomino-perineal exci-
sion for carcinoma of the rectum and the terminal portion of
the pelvic colon. Lancet 1908;ii:1812–3.
2. Miles WE. Cancer of the Rectum. London: Harrisons, 1926.
3. Surtees P, Ritchie JK, Phillips RK. High versus low ligation of the
inferior mesenteric artery in rectal cancer. Br J Surg 1990;77:
618–21.
4. Harnsberger JR, Vernava VM 3rd, Longo WE. Radical
abdominopelvic lymphadenectomy: historic perspective and
current role in the surgical management of rectal cancer. 
Dis Colon Rectum 1994;37:73–87.
5. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal
cancer surgery: the clue to pelvic recurrence? Br J Surg 1982;
69:613–6.
6. Kapiteijn E, Marijinen CAM, Colenbrander AC. Local recur-
rence in patients with rectal cancer diagnosed between 1988
and 1992: a population-based study in the west Netherlands.
Eur J Surg Oncol 1998;24:528–35.
7. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant
treatment of colorectal cancer. CA Cancer J Clin 2007;57:168–85.
8. Marks G, Mohiuddin M, Rakinic J. New hope and promise 
for sphincter preservation in the management of cancer of the
rectum. Semin Oncol 1991;18:388–98.
9. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or post-
operative irradiation in adenocarcinoma of the rectum: final
treatment results of a randomized trial and an evaluation of late
secondary effects. Dis Colon Rectum 1993;36:564–72.
10. Valenti V, Hernandez-Lizoain JL, Baixauli J, Pastor C, Aristu J,
Diaz-Gonzalez J, Beunza JJ, et al. Analysis of early postopera-
tive morbidity among patients with rectal cancer treated with
and without neoadjuvant chemoradiotherapy. Ann Surg Oncol
2007;14:1744–51.
J Chin Med Assoc • April 2009 • Vol 72 • No 4182
C.M. Twu, et al






0 0 (0) 5 (13.9)
A + B 2 (28.6) 20 (55.6)
B2 2 (28.6) 0 (0)
C 3 (42.9) 11 (30.6)
CRM 0.010‡
R0 4 (57.1) 35 (97.2)
R1 + R2 3 (42.9) 1 (2.8)
Poorly/A-V-N 0.215‡
+ 4 (57.1) 11 (30.6)
− 3 (42.9) 25 (69.4)
*Data presented as n (%); †Pearson’s χ2 test; ‡Fisher’s exact test. LR = local
recurrence; CRM = circumferential radial margin; A-V-N = cancer invasion to
artery, vein or nerve.
